Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and Rosalie Kaplan Endowed Chair in Medical Oncology, City of Hope explains the ideal patient to receive Alimta plus Keytrude based on data and results from KEYNOTE-189.
Ideal Patient to Receive Alimata Plus Keytruda: KEYNOTE-189
